MarketVIEW Hospital / AMR Diseases  -  Publishing Q4 2026

Clostridioides difficile
Vaccines Forecast

Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated infectious diarrhoea in the United States, and there is still no licensed vaccine. The field has been reset by a single large Phase 3 and a re-licensed European asset. VAMV001 is VacZine Analytics' independent commercial assessment of what a first-in-class C. difficile vaccine could be worth, and to whom.

462,100 US Cases in 2017 (CDC) Pfizer Phase 3 BEETHOVEN: 32,500 Adults 65+ No Licensed Vaccine to Date Publishing Q4 2026
Product catalogue
VAMV001
Publishing Q4 2026

Format
PDF executive deck + Excel forecast model
Markets modelled
United States first, then major markets
Scenarios
Uptake, pricing, launch & efficacy
Approach
Target-population demand model
Edition
Title refresh (first edition 2007)
Publication
Q4 2026
Availability
Syndicated / bespoke
462,100
Estimated US CDI cases in 2017
(CDC; 476,400 in 2011)
1 in 5
Patients with a first CDI episode
go on to a recurrence
32,500
Adults aged 65+ enrolled in
Pfizer's Phase 3 BEETHOVEN trial
0
Licensed C. difficile vaccines
to date
Disease background

A toxin-driven hospital infection that treatment alone has not contained

This section sets out the disease background and epidemiology of Clostridioides difficile infection, and why prevention, rather than further treatment, is the remaining unmet need.

CDC burden estimates, 2011 and 2017

Pathogen overview - Clostridioides difficile

Clostridioides difficile is a spore-forming, toxin-producing anaerobic bacterium and the leading cause of healthcare-associated infectious diarrhoea in the United States. Disease is driven by toxins A and B, with a binary toxin added in hypervirulent strains, and it typically follows disruption of the gut microbiome by antibiotics. CDC's first national estimate put the 2011 burden at 453,000 cases, 83,000 first recurrences and 29,300 deaths. A later CDC analysis estimated 476,400 cases in 2011 and 462,100 in 2017.

The burden has shifted, not disappeared. Between 2011 and 2017 healthcare-associated CDI fell by 36%, but community-associated CDI was unchanged. Age is the dominant risk factor, with an incidence rate ratio of 8.65 for adults aged 65 and over, and about one in five patients with a first episode goes on to a recurrence. Acute-care costs have been estimated at up to $4.8 billion a year in the United States. In Europe the burden is also substantial, with surveillance led by ECDC, and the report treats Europe from the published surveillance record.

Treatment has not solved recurrence. Antibiotics clear the infection but do not prevent it returning, and the US now has approved microbiome-based therapies aimed at reducing recurrence. None of these addresses the underlying exposure risk in hospitalised, care-home, antibiotic-exposed and immunosuppressed patients, which is why a vaccine for adults aged 65 and over and other high-risk groups remains the central commercial question.

2026 462,100 US cases (2017)  |  36% fall in healthcare-associated CDI, community-associated unchanged  |  Phase 3 reads out late 2028  |  still no licensed vaccine
Note on sources and figures US burden estimates follow the CDC national estimates for 2011 and the later CDC analysis covering 2011 to 2017. Trial details are taken from the ClinicalTrials.gov registry entry for BEETHOVEN (NCT07282665). The report updates all figures to the latest available data at publication.
Product & competitor landscape

One Phase 3 programme now carries the field

Pfizer's second-generation candidate is in a 32,500-participant Phase 3, and a re-licensed European asset is expected in the clinic around 2027. Earlier programmes have stalled or been discontinued, so the near-term market is shaped largely by a single readout.

  • PfizerPhase 3
    PF-07831694 (BEETHOVEN, NCT07282665) Second-generation toxoid vaccine
    A placebo-controlled Phase 3 in about 32,500 adults aged 65 and over, started in December 2025, with primary completion registered for December 2028. The primary endpoint is the first episode of medically attended, clinically meaningful primary CDI, with surveillance of up to about 3.5 years.
  • PfizerFirst generation, 2022
    First-generation C. difficile vaccine (CLOVER) Missed primary endpoint
    The CLOVER Phase 3 did not meet its primary endpoint. Pfizer reported 100% efficacy against medically attended CDI (0 of 17 vaccine-group cases were medically attended, versus 11 of 25 in the placebo group) and a 75% reduction in the median duration of infection, which underpins the second-generation programme.
  • Elaris (Vienna)Preclinical
    Next-generation candidate based on Valneva VLA84 technology Exclusive global licence, March 2026
    Elaris holds an exclusive global licence to Valneva's C. difficile technology and is adding proprietary components to broaden protection. IND-enabling development is under way, with clinical studies targeted for around 2027.
  • NovavaxPreclinical
    Multivalent polypeptide vaccine Patent granted
    A granted patent covers a multivalent polypeptide combining CDT, toxin A and portions of toxin B, supported by mouse lethal-toxin challenge studies. No public clinical timeline.
  • Idorsia, Vaxxilon, MatrivaxEarlier stage
    Earlier-stage programmes Various
    Earlier-stage candidates are tracked in the report alongside programmes that have been discontinued, including Sanofi's Cdiffense vaccine, which was stopped after its Phase 3 trial in 2017.
Market reset
Late 2028 readout

The commercial picture is being reset by one large Phase 3 and a re-licensed European asset. VAMV001 models target populations, second-generation versus first-generation expectations after CLOVER, and uptake and value scenarios for a first-in-class vaccine, United States first.

Scope of analysis

Six analytical layers - one commercial picture

A target-population demand model for a first-in-class C. difficile vaccine, with scenarios that bracket the Phase 3 outcome and a pipeline review updated to the latest registry and company data.

Demand & revenue forecast

Demand and revenue forecast for a first-in-class C. difficile vaccine, United States first, then other major markets.

Scenarios

Scenarios on efficacy, uptake, pricing and launch timing, bracketing the outcome of the Phase 3 readout.

Target populations

Adults aged 65 and over and other high-risk groups, including hospitalised, care-home, antibiotic-exposed and immunosuppressed patients.

Pipeline & competitor review

Registry-verified review of Pfizer, Elaris, Novavax and earlier-stage programmes, with discontinued programmes tracked.

Second versus first generation

What the CLOVER result means for expectations of second-generation vaccines, and where value is won or lost.

Disease burden & epidemiology

CDI burden and the hospital to community shift, updated to the latest available data.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the target-population and scenario framework. Full revenue outputs, scenario assumptions and market data are in the licensed model.

Target populationGeographySettingVaccine statusRevenue scenario
Adults aged 65 and overUnited StatesCommunity and long-term carePre-licensureModelled
Hospitalised high-risk adultsUnited StatesAcute carePre-licensureModelled
Immunosuppressed adultsUnited StatesSpecialist carePre-licensureModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll marketsAll settingsAll scenarios$███m
Full model in the licensed workbook
United States first · Target-population demand model · Scenarios on efficacy, uptake, pricing and launch timing
Register interest →
Deliverables

What you receive

An executive presentation and a fully interactive forecast model, built for organisations evaluating the first-in-class C. difficile vaccine opportunity.

  • Executive presentation (PDF) - disease burden, pipeline and the full commercial assessment, with supporting narrative and references
  • Excel forecast model - interactive scenario dashboard with demand and revenue by target population and year
  • Scenario set - efficacy, uptake, pricing and launch-timing scenarios with documented assumptions and sources
  • Pipeline and competitor intelligence - registry-verified review of the clinical field, including discontinued programmes
  • Updated epidemiology - CDI burden and the hospital to community shift, updated to the latest available data
  • Briefing call - a walkthrough of the findings with the analyst team on request
Target audience

Built for organisations weighing the C. difficile vaccine opportunity

Most valuable to teams evaluating the market against their own pipeline, BD ambitions or investment thesis ahead of the Phase 3 readout.

Vaccine developers

Positioning and commercial feasibility for C. difficile candidates at any stage, informed by the Pfizer Phase 3 and the CLOVER result.

Corporate strategy & BD

Size and structure the opportunity, and test licensing and partnering options ahead of a late 2028 readout.

Investors & analysts

Independent assessment of pipeline risk and commercial upside for due diligence on Pfizer, Elaris, Valneva and other entrants.

Hospital & infection-control stakeholders

Demand modelling for hospitalised, care-home and antibiotic-exposed patient groups.

Researchers & academia

Disease burden, epidemiology and R&D landscape for grant and translational research planning.

Market access & policy

Value and pricing context for a first-in-class vaccine in older adults and high-risk groups.

About this analysis · VAMV001

VAMV001 is the Q4 2026 refresh of VacZine Analytics' Clostridioides difficile vaccines title, first published in 2007. It assesses the commercial opportunity for a first-in-class vaccine, covering target populations, expectations for second-generation candidates after CLOVER, and uptake and value scenarios, United States first.

The analysis draws on CDC burden estimates and a pipeline verified against trial registries and company disclosures. Where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV001 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest in the Q4 2026 syndicated MarketVIEW edition. Single-licence and multi-user options are available on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc C. difficile analysis, and a briefing call is included on request.